This preprint is under consideration at BMC Cancer. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Lei Fan
Fudan University Shanghai Cancer Center, Fudan University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Introduction: Normalization cancer immunotherapy is a new strategy to treat breast cancer. Sialic acid binding Ig-like lectin 15 (Siglec-15) is a new potential target for normalization cancer immunotherapy. In this study, we evaluated the role of Siglec15 in breast cancer and investigated the influence of Siglec15 on the microenvironment of infiltrating immune cells in the cancer.
Methods: We performed immunhistochemical staining to analyze Siglet-15 expression in primary invasive breast cancer tissue microarrays. The tissue specimens were from 90 patients. Furthermore, The relationship between Siglec15 and clinicopathological features was analyzed with logistic regression and the Wilcoxon signed-rank test. The association between clinical characteristics and overall survival in the Cancer Genome Atlas (TCGA) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) patients was assessed.
Results: Immunhistochemical staining of tissue microarrays showed that Siglet-15 had higher expression in breast cancer tissues than those in adject normal tissues. Breast cancer tissues had higher Siglec15 expression than normal tissues. Kaplan-Meier survival analysis suggested that triple negative breast cancer with high Siglec15 expression had poorer survival than those with lower Siglec15 expression (p=0.042). Furthermore, high Siglec15 expression group had low activated dendritic cells, follicular helper T cells, and M1 macrophages.
Conclusions: Siglet-15 had high expression in breast cancer tissues. High Siglec15 expression is associated with low activated dendritic cells, follicular helper T cells, and M1 macrophages proportions in breast cancer tissue, and predicts poor prognosis in triple negative breast cancer. Siglec15 expression may be a potential prognostic molecular marker of poor survival in breast cancer.
Keywords
Breast cancer, Sialic acid binding Ig-like lectin 15 (Siglec-15), Gene expression, M1 macrophages, dendritic cells, Cancer survival
Figure 1
Figure 2
Figure 3
Figure 4
No competing interests reported.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 10 Nov, 2021
No community comments so far
Reviewers agreed
On 17 Nov, 2021
Reviewers invited
Invitations sent on 05 Nov, 2021
Editor assigned
On 05 Nov, 2021
Editor invited
On 05 Nov, 2021
Submission checks complete
On 05 Nov, 2021
First submitted
On 26 Oct, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at BMC Cancer. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Lei Fan
Fudan University Shanghai Cancer Center, Fudan University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 10 Nov, 2021
No community comments so far
Reviewers agreed
On 17 Nov, 2021
Reviewers invited
Invitations sent on 05 Nov, 2021
Editor assigned
On 05 Nov, 2021
Editor invited
On 05 Nov, 2021
Submission checks complete
On 05 Nov, 2021
First submitted
On 26 Oct, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Introduction: Normalization cancer immunotherapy is a new strategy to treat breast cancer. Sialic acid binding Ig-like lectin 15 (Siglec-15) is a new potential target for normalization cancer immunotherapy. In this study, we evaluated the role of Siglec15 in breast cancer and investigated the influence of Siglec15 on the microenvironment of infiltrating immune cells in the cancer.
Methods: We performed immunhistochemical staining to analyze Siglet-15 expression in primary invasive breast cancer tissue microarrays. The tissue specimens were from 90 patients. Furthermore, The relationship between Siglec15 and clinicopathological features was analyzed with logistic regression and the Wilcoxon signed-rank test. The association between clinical characteristics and overall survival in the Cancer Genome Atlas (TCGA) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) patients was assessed.
Results: Immunhistochemical staining of tissue microarrays showed that Siglet-15 had higher expression in breast cancer tissues than those in adject normal tissues. Breast cancer tissues had higher Siglec15 expression than normal tissues. Kaplan-Meier survival analysis suggested that triple negative breast cancer with high Siglec15 expression had poorer survival than those with lower Siglec15 expression (p=0.042). Furthermore, high Siglec15 expression group had low activated dendritic cells, follicular helper T cells, and M1 macrophages.
Conclusions: Siglet-15 had high expression in breast cancer tissues. High Siglec15 expression is associated with low activated dendritic cells, follicular helper T cells, and M1 macrophages proportions in breast cancer tissue, and predicts poor prognosis in triple negative breast cancer. Siglec15 expression may be a potential prognostic molecular marker of poor survival in breast cancer.
Figure 1
Figure 2
Figure 3
Figure 4
No competing interests reported.
Loading...